Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ALX ONCOLOGY HOLDINGS INC (ALXO)

ALX Oncology names Scott Garland chairman after Corey Goodman resigns

Neutral Impact 3 of 5 leadership Written later

ALX Oncology said Chairman Corey Goodman, Ph.D. resigned from the board effective June 29, 2026, for personal reasons and not over any disagreement with the company. The board named independent director Scott Garland as chairman and reset committee memberships, and the company also appointed Michael Listgarten as General Counsel. The filing reports no financial results, so the change is a governance update rather than a change in operating performance.

Key points

  • Corey Goodman, Ph.D. resigned as chairman and as a director, effective close of business June 29, 2026
  • Scott Garland, an independent director since November 2022, became chairman effective June 29, 2026
  • Garland joins the Audit Committee; Chris Takimoto, M.D., Ph.D., chairs the Compensation Committee
  • Michael Listgarten was appointed General Counsel, effective immediately, per the June 30, 2026 press release

The filing

CompanyALX ONCOLOGY HOLDINGS INC (ALXO)
Form8-K, current report
Filed with the SECJun 30, 2026, 4:01 PM ET
Accession number0001193125-26-290447

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.